Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) EBT Margin (2021 - 2025)

Janux Therapeutics (JANX) has disclosed EBT Margin for 5 consecutive years, with 243.13% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 614844.0% to 243.13% in Q3 2025 year-over-year; TTM through Dec 2025 was 1136.25%, a 48463.0% decrease, with the full-year FY2025 number at 1136.25%, down 48463.0% from a year prior.
  • EBT Margin was 243.13% for Q3 2025 at Janux Therapeutics, up from 6391.57% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 66.98% in Q2 2024 to a low of 6391.57% in Q3 2024.
  • A 5-year average of 1126.13% and a median of 837.06% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -593198bps in 2024, then soared 614844bps in 2025.
  • Janux Therapeutics' EBT Margin stood at 830.2% in 2021, then surged by 32bps to 564.67% in 2022, then increased by 15bps to 477.77% in 2023, then crashed by -1238bps to 6391.57% in 2024, then soared by 96bps to 243.13% in 2025.
  • Per Business Quant, the three most recent readings for JANX's EBT Margin are 243.13% (Q3 2025), 6391.57% (Q3 2024), and 66.98% (Q2 2024).